Non-executive director Steven Coffey acquired 8,000 shares in an indirect interest on June 1 and 2, increasing his holding to 426,250 shares with another 8,015 held in a direct interest.
On May 31 executive director and CEO Dr James Garner purchased 10,000 shares in a direct interest, increasing the number of securities held to 430,000.
Non-executive director Bryce Carmine acquired 20,000 shares on May 31 in a direct interest, increasing his holding to 372,692 shares.
This follows multiple purchases made by KZA directors on May 3.
March quarter highlights
The company kicked off 2021 with a trifecta of March quarter licensing deals, leaving it "a vastly stronger and more substantial business", according to CEO Dr James Garner.
During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million by the end of March.
Reflecting on its strong progress, shares in the company have risen from A$0.77 cents at the market close on November 4 to A$1.88 on April 8, a new high of almost six years, while the market cap is now approximately A$180.8 million.